Based on the purported disinhibition of pyramidal glutamatergic output as a core feature of schizophrenia, modulation of glutamate signalling at the postsynaptic levels via group I metabotropic receptors, and in particular mGluR5s, has gained interest as a potential promising therapeutic strategy. This evidence concerns the gene GRM5 and schizophrenia.